Core Points - Akanda Corp. has announced a public offering of 1,500,000 common shares at a price of $1.00 per share, with gross proceeds estimated at approximately $1,500,000 before expenses [2][3] - The offering is expected to close on about October 3, 2024, pending customary closing conditions [3] - The net proceeds will be used for capital expenditures, operating capacity, working capital, potential milestone payments for a Canadian property, general corporate purposes, and refinancing existing debt [3] Company Overview - Akanda Corp. is an international medical cannabis company operating in Europe and North America, focused on cultivating and distributing high-quality medical cannabis and wellness products [5] - The company's mission is to provide safe, reliable, and accessible cannabis products while promoting sustainable business practices [5]

Group 1 - Akanda Corp. has secured a hemp cultivation license in Canada, which is linked to a prior agreement with 1107385 B.C. LTD, enhancing its strategic initiatives in the Canadian cannabis market [2] - This development underscores Akanda's commitment to its strategic vision and aims to solidify its position as a leader in the global cannabis industry [2] Group 2 - Akanda is an international medical cannabis and wellness platform, focused on improving access to high-quality and affordable products [3] - The company's portfolio includes CanMart, a fully licensed pharmaceutical importer and distributor in the UK, supplying pharmacies and clinics [3] - Akanda has acquired rights to develop a farming property in British Columbia, which will include THC and cannabinoid (CBD) facilities [3]

Group 1 - Akanda (NASDAQ:AKAN) stock is experiencing a significant rise with over 6.8 million shares traded, far exceeding its daily average of approximately 1.3 million shares and its float of 760,620 units [1] - The increase in trading volume occurs without any clear news or announcements from Akanda, including no press releases or SEC filings, and there is no analyst coverage contributing to the rally [1] - AKAN is classified as a penny stock, with a prior closing price of $1.45 and a market capitalization of $2.779 million [1] Group 2 - AKAN stock has risen by 34.1% as of Friday morning, but investors are advised to be cautious due to the lack of news and the sudden surge in trading volume, which may indicate a pump and dump scenario [2] - The current situation makes AKAN stock a risky investment, prompting investors to be careful about acquiring shares in the company [2]

Core Points - Akanda Corporation has completed sales of its securities under an existing Form F-3 shelf registration, raising approximately $4.98 million in gross proceeds since its effectiveness on January 29, 2024 [2][3]. - The company has maxed out its $5 million capacity under the F-3 shelf registration and will not raise further funds under this statement, indicating future offerings will require a new registration statement [3]. Company Overview - Akanda is an international medical cannabis and wellness platform focused on improving access to high-quality and affordable products [4]. - The company's portfolio includes CanMart, a UK-based licensed pharmaceutical importer and distributor, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic in the UK [4]. - Akanda has acquired rights to develop a farming property in British Columbia for THC and cannabinoid (CBD) facilities [4].

Core Points - Akanda Corp has regained compliance with Nasdaq's Minimum Bid Price Requirement as of June 7, 2024, after meeting the necessary criteria for 10 consecutive business days [2][3]. Company Overview - Akanda Corp is an international medical cannabis company focused on improving access to high-quality and affordable products. Its portfolio includes CanMart, a licensed pharmaceutical importer and distributor in the UK, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic [4]. - The company is also developing a Canadian farming property in British Columbia for THC and cannabinoid (CBD) production [4].

Group 1 - Akanda (NASDAQ:AKAN) stock is experiencing significant trading activity, with over 6.3 million shares changing hands, a substantial increase from its daily average of approximately 590,000 shares [1] - The company recently executed a reverse stock split on a one-for-40 basis to increase its share price above the minimum required for listing on the Nasdaq Exchange [1] - As of Friday morning, AKAN stock has surged by 133.4% [2] Group 2 - AKAN stock has a low float of about 2.74 million units, contributing to its volatility and potential for significant price movements [2] - The stock is categorized as a penny stock, which may attract traders looking for quick profits, potentially leading to pump and dump scenarios [2] - The current trading activity may indicate speculative behavior, and investors are advised to be cautious as the stock could experience a rapid decline after the initial surge [2]

Core Viewpoint - Akanda Corp. plans to implement a 1-for-40 reverse stock split effective May 23, 2024, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][2]. Company Overview - Akanda Corp. is an international medical cannabis company focused on improving access to high-quality and affordable products [3]. - The company's portfolio includes CanMart, a UK-based licensed pharmaceutical importer and distributor, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic in the UK [3]. - Akanda has acquired rights to develop a farming property in British Columbia, Canada, for THC and cannabinoid (CBD) facilities [3]. Reverse Stock Split Details - The reverse stock split will convert every 40 shares into one share, with no fractional shares issued; any fractions will be rounded down [2]. - This action was approved by the company's board of directors and shareholders, and the company will file Articles of Amendment with the Ontario Ministry of Government and Consumer Services [2]. - The new CUSIP number for the ordinary shares post-split will be 00971M304 [1].

Company Overview - Akanda Corp. is an international medical cannabis company focused on improving access to high-quality and affordable products [6] - The company's portfolio includes CanMart, a UK-based licensed pharmaceutical importer and distributor, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic in the UK [6] Offering Details - Akanda has closed its second registered direct offering, selling 2,491,381 common shares at a price of $0.1031 and 12,057,600 pre-funded warrants at $0.103 per share [2] - The gross proceeds from this offering were approximately $1,500,000, which will be used for capital expenditures, operating capacity, working capital, general corporate purposes, and refinancing existing debt [3] Regulatory Compliance - The securities were offered under an effective shelf registration statement on Form F-3, which was declared effective on January 29, 2024 [4] - The final prospectus supplement related to the offering was filed with the SEC on May 20, 2024, and is available on the SEC's website [4]

Core Points - Akanda Corp has successfully closed a registered direct offering, selling 2,491,381 common shares at $0.1031 each and 21,756,922 pre-funded warrants at $0.103 each, generating gross proceeds of approximately $2,500,000 [2][3]. Group 1: Offering Details - The offering included 2,491,381 common shares and 21,756,922 pre-funded warrants, with the warrants being immediately exercisable at $0.0001 per share [2][3]. - The offering was conducted under an effective shelf registration statement filed with the SEC, which was declared effective on January 29, 2024 [4]. Group 2: Use of Proceeds - Akanda intends to utilize the net proceeds for capital expenditures, enhancing operating capacity, working capital, general corporate purposes, and refinancing or repaying existing debt [3]. Group 3: Company Overview - Akanda is an international medical cannabis company focused on improving access to high-quality and affordable products, with a portfolio that includes CanMart, a licensed pharmaceutical importer and distributor in the UK [6]. - The company is also developing a Canadian farming property in British Columbia for THC and cannabinoid (CBD) production [6].

Core Viewpoint - Akanda Corp. has announced a registered direct offering to raise approximately $2.5 million through the sale of common shares and pre-funded warrants, aimed at general working capital and corporate expenses [2][3]. Group 1: Offering Details - The offering includes 2,491,381 common shares priced at $0.1031 each and 21,756,922 pre-funded warrants at $0.103 per share, with the warrants being immediately exercisable at $0.0001 [2]. - The gross proceeds from the offering are estimated to be around $2,500,000 before deducting fees and expenses [3]. - The offering is expected to close on or about May 17, 2024, pending customary closing conditions [3]. Group 2: Regulatory Information - The offering is conducted under an effective shelf registration statement on Form F-3, previously filed with the SEC and effective since January 29, 2024 [4]. - A final prospectus related to the offering will be filed with the SEC and will be available for free on the SEC's website [4]. Group 3: Company Overview - Akanda Corp. is an international medical cannabis company focused on improving access to high-quality and affordable products [6]. - The company's portfolio includes CanMart, a licensed pharmaceutical importer and distributor in the UK, and partnerships with Cellen Life Sciences' Leva Clinic [6]. - Akanda is also developing a Canadian farming property in British Columbia for THC and CBD facilities [6].